PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries

Authors

  • Anna Langenbruch Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Germany
  • Nicole Mohr Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Germany
  • Valerie Andrees Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Germany
  • Ihno Kessens Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Germany
  • Adam Reich Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland
  • Magdalena Czarnecka-Operacz Department of Dermatology, Medical University of Poznan, Poland
  • Luis Puig Department of Dermatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
  • Esteban Dauden Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain
  • Lars Iversen Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark
  • Matthias Augustin Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Germany

DOI:

https://doi.org/10.2340/actadv.v103.6532

Keywords:

health services research, psoriasis, quality of life

Abstract

Enhanced treatment options for psoriasis and growing use of guidelines increased the potential to better quality of psoriasis care in Europe. The aim of the PsoBarrier EU study is to compare the quality and processes of psoriasis care in four European countries with different healthcare systems, based on validated quality indicators. This cross-sectional survey was conducted in dermatology centres in Denmark, Germany, Poland and Spain on 1,304 patients, using standardized patient and physician questionnaires. Measured by quality of psoriasis care indicators, patients in Poland had the most critical outcomes, such as the highest disease severity (Psoriasis Area and Severity Index; PASI) and lowest health-related quality of life (Dermatology Life Quality Index; DLQI). This indicates differences in psoriasis care, with Polish participants experiencing more severe psoriasis and its consequences. Differences in the healthcare systems, which create barriers to accessing treatments, could explain variations in quality of care.

Downloads

Download data is not yet available.

References

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590.

https://doi.org/10.1136/bmj.m1590 DOI: https://doi.org/10.1136/bmj.m1590

Ferreira BIRC, Da Abreu JLPC, Reis JPGD, Da Figueiredo AMC. Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation. J Clin Aesthet Dermatol 2016; 9: 36-43.

Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol 2017; 77: 425-440.e2.

https://doi.org/10.1016/j.jaad.2017.05.019 DOI: https://doi.org/10.1016/j.jaad.2017.05.019

Halioua B, Chelli C, Misery L, Taieb J, Taieb C. Sleep disorders and psoriasis: an update. Acta Derm Venereol 2022; 102: adv00699.

https://doi.org/10.2340/actadv.v102.1991 DOI: https://doi.org/10.2340/actadv.v102.1991

Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 559-568.

https://doi.org/10.1586/14737167.2014.914437 DOI: https://doi.org/10.1586/14737167.2014.914437

Korte J de, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-147.

https://doi.org/10.1046/j.1087-0024.2003.09110.x DOI: https://doi.org/10.1046/j.1087-0024.2003.09110.x

Jungen D, Augustin M, Langenbruch A, Zander N, Reich K, Strömer K, et al. Cost-of-illness of psoriasis - results of a German cross-sectional study. J Eur Acad Dermatol Venereol 2018; 32: 174-180.

https://doi.org/10.1111/jdv.14543 DOI: https://doi.org/10.1111/jdv.14543

Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R. Psoriasis causes significant economic burden to patients. Dermatol Ther (Heidelb) 2014; 4: 115-124.

https://doi.org/10.1007/s13555-014-0053-2 DOI: https://doi.org/10.1007/s13555-014-0053-2

Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, et al. Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology (Basel) 2009; 219: 54-58.

https://doi.org/10.1159/000218161 DOI: https://doi.org/10.1159/000218161

Nast A, Altenburg A, Augustin M, Boehncke W-H, Härle P, Klaus J, et al. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 1: Therapieziele und Therapieempfehlungen. J Dtsch Dermatol Ges 2021; 19: 934-951.

https://doi.org/10.1111/ddg.14508_g DOI: https://doi.org/10.1111/ddg.14508_g

Augustin M, Eissing L, Langenbruch A, Enk A, Luger T, Maaßen D, et al. The German National Program on Psoriasis Health Care 2005-2015: results and experiences. Arch Dermatol Res 2016; 308: 389-400.

https://doi.org/10.1007/s00403-016-1637-8 DOI: https://doi.org/10.1007/s00403-016-1637-8

Daudén E, Pujol RM, Sánchez-Carazo JL, Toribio J, Vanaclocha F, Puig L, et al. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: the VACAP study. Actas Dermosifiliogr 2013; 104: 807-814.

https://doi.org/10.1016/j.ad.2013.03.005 DOI: https://doi.org/10.1016/j.ad.2013.03.005

Tribó MJ, Turroja M, Castaño-Vinyals G, Bulbena A, Ros E, García-Martínez P, et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Derm Venereol 2019; 99: 417-422.

https://doi.org/10.2340/00015555-3114 DOI: https://doi.org/10.2340/00015555-3114

Ruiz Genao DP, Carretero G, Rivera-Diaz R, Carrascosa JM, Sahuquillo-Torralba A, Herrera-Acosta E, et al. Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry. Br J Dermatol 2022; 187: 817-820.

https://doi.org/10.1111/bjd.21763 DOI: https://doi.org/10.1111/bjd.21763

Loft ND, Egeberg A, Rasmussen MK, Bryld LE, Gniadecki R, Dam TN, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a Danish nationwide study. Acta Derm Venereol 2019; 99: 1224-1230.

https://doi.org/10.2340/00015555-3331 DOI: https://doi.org/10.2340/00015555-3331

Purzycka-Bohdan D, Kisielnicka A, Zabłotna M, Nedoszytko B, Nowicki RJ, Reich A, et al. Chronic plaque psoriasis in Poland: disease severity, prevalence of comorbidities, and quality of life. J Clin Med 2022; 11: 1254.

https://doi.org/10.3390/jcm11051254 DOI: https://doi.org/10.3390/jcm11051254

Schwarz CW, Loft N, Rasmussen MK, Nissen CV, Dam TN, Ajgeiy KK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol 2021; 101: adv00579.

https://doi.org/10.2340/actadv.v101.351 DOI: https://doi.org/10.2340/actadv.v101.351

OECD/European Observatory on Health Systems and Policies, editor. Denmark: Country Health Profile 2021, State of Health in the EU. Paris/Brussels: OECD Publishing; 2021.

OECD/European Observatory on Health Systems and Policies, editor. Germany: Country Health Profile 2021, State of Health in the EU. Paris/Brussels: OECD Publishing; 2021.

OECD/European Observatory on Health Systems and Policies, editor. Poland: Country Health Profile 2021, State of Health in the EU. Paris/Brussels: OECD Publishing; 2021.

OECD/European Observatory on Health Systems and Policies, editor. Spain: Country Health Profile 2021, State of Health in the EU. Paris/Brussels: OECD Publishing; 2021.

Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34: 2461-2498.

https://doi.org/10.1111/jdv.16915 DOI: https://doi.org/10.1111/jdv.16915

Danish Health Authority. National clinical guideline on psoriasis: quick guide; 2016 [cited 2023 May 10]. Available from: https://www.sst.dk/en/English/publications/2016/National-clinical-guideline-on-psoriasis.

Reich A, Adamski Z, Chodorowska G, Kaszuba A, Krasowska D, Lesiak A, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. pd 2020; 107: 92-108.

https://doi.org/10.5114/dr.2020.95258 DOI: https://doi.org/10.5114/dr.2020.95258

Carrascosa JM, Puig L, Belinchón Romero I, Salgado-Boquete L, Del Alcázar E, Andrés Lencina JJ, et al. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. "Conceptos y manejo general de la psoriasis con terapia biológica". Actas Dermosifiliogr 2022; 113: 261-277.

https://doi.org/10.1016/j.ad.2021.10.003 DOI: https://doi.org/10.1016/j.ad.2021.10.003

WHO. Global report on psoriasis. Geneva: World Health Organization; 2016.

Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.

https://doi.org/10.1159/000250839 DOI: https://doi.org/10.1159/000250839

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.

https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x

Bundesärztekammer. Ergebnisse der Ärztestatistik zum 31.12.2020: Tabelle 3: Ärztinnen/Ärzte nach Bezeichnungen und Tätigkeitsarten. Available from: https://www.bundesaerztekammer.de/baek/ueber-uns/aerztestatistik/aerztestatistik-2020.

Naczelna Izba Lekarska. Central Register of Physicians [cited 2020 Mar 3]. Available from: https://nil.org.pl/uploaded_files/1583227918_zestawienie-nr-04.pdf.

Barber-Pérez P, González López-Valcárcel B. Informe Oferta-Necesidad de Especialistas Médicos 2021-2035: EcoSalud. Universidad de Las Palmas de Gran Canaria; 2022. Available from: https://www.sanidad.gob.es/areas/profesionesSanitarias/profesiones/necesidadEspecialistas/docs/2022Estudio_Oferta_Necesidad_Especialistas_Medicos_2021_2035V3.pd.f

Danish Health Data Agency. Arbejdsstyrken af sundhedsuddannede: Opgørelserne viser arbejdsstyrken af antal sundhedsuddannede fordelt på år, faggrupper, herkomst, speciale, alder og køn, uddannelsesland, brancher og sektorer, region (2000-2020); 2020. Available from: https://www.esundhed.dk/Emner/Beskaeftigede-i-sundhedsvaesnet/Arbejdsstyrken-af-sundhedsuddannede.

OECD. Health at a Glance 2019: OECD indicators. Paris: OECD; 2019.

Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF. Stigmatization and Quality of Life in Patients with Psoriasis. Dermatol Ther (Heidelb) 2020; 10: 285-296.

https://doi.org/10.1007/s13555-020-00363-1 DOI: https://doi.org/10.1007/s13555-020-00363-1

Sommer R, Topp J, Mrowietz U, Zander N, Augustin M. Perception and determinants of stigmatisation of people with psoriasis in the German population. J Eur Acad Dermatol Venereol 2020; 34: 2845-2855.

https://doi.org/10.1111/jdv.16436 DOI: https://doi.org/10.1111/jdv.16436

Qureshi AA, Awosika O, Baruffi F, Rengifo-Pardo M, Ehrlich A. Psychological therapies in management of psoriatic skin disease: a systematic review. Am J Clin Dermatol 2019; 20: 607-624.

https://doi.org/10.1007/s40257-019-00437-7 DOI: https://doi.org/10.1007/s40257-019-00437-7

Published

2023-08-31

How to Cite

Langenbruch, A. ., Mohr, N., Andrees, V., Kessens, I., Reich, A., Czarnecka-Operacz, M., … Augustin, M. (2023). PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries. Acta Dermato-Venereologica, 103, adv6532. https://doi.org/10.2340/actadv.v103.6532